AKT1 and prostate cancer: However, inhibition of this pathway helps rescue drug sensitivity in vitro and in vivo.818,819 Furthermore, enhanced activity of the protein kinase B (AKT)/mTOR complex 1 (mTORC1) signaling pathway is also responsible for drug resistance to BET inhibitors in prostate cancer.820 In another study on HDAC resistance in solid tumors, the potential role of the activation of some kinases and downstream pathways was also reported.821 Additionally, altered TME may be one of the culprits in promoting drug resistance.